Pfizer to Buy ReViral for $525 Million
(PLX AI) - Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates for total consideration of up to $525 million.• ReViral is a privately held, clinical-stage biopharmaceutical
Source: finanznachrichten.de